OPAL (Open@LaTrobe) (La Trobe University)
November 10, 2025
An optimized extraction and quantitative nuclear magnetic resonance (qNMR) method accurately measures psilocybin and psilocin in dried Psilocybe cubensis mushrooms. The technique detects both compounds simultaneously with high reproducibility and requires no calibration standards. Analysis of user-provided and laboratory-grown samples revealed large variability in tryptamine content and psilocybin-to-psilocin ratios, suggesting storage conditions affect alkaloid stability. qNMR offers a rapid, nondestructive alternative to conventional chromatography for routine analysis, potentially supporting quality control in clinical and regulatory settings for psychedelic mushrooms.
OPAL (Open@LaTrobe) (La Trobe University)
November 5, 2025
Alberto Liardi (22305679), Fernando E. Rosas (9595503), Robin L. Carhart-Harris (5923571) et al.
The abstract discusses differences between drug and placebo conditions in terms of partial information decomposition (PID) atoms, using two specific PID methods: MMI and CCS. It focuses on how these methods quantify unique and redundant information contributions in a system, likely in the context of neural or cognitive data. The text is too brief to convey a complete finding or argument.
OPAL (Open@LaTrobe) (La Trobe University)
November 5, 2025
Alberto Liardi (22305679), Fernando E. Rosas (9595503), Robin L. Carhart-Harris (5923571) et al.
The figure displays results for LSD, ketamine, and psilocybin across three rows: raw PID atoms, NMI-normalized PID atoms, and NuMIT-normalized PID atoms. Dashed lines mark zero. P-values were computed using a one-sample t-test against a zero-mean null hypothesis, with asterisks indicating p < 0.001. No further details on findings or sample are provided.
OPAL (Open@LaTrobe) (La Trobe University)
September 19, 2025
Adding a single 25 mg dose of psilocybin to an 8-week Mindfulness-Based Stress Reduction (MBSR) program reduced depressive symptoms more than MBSR alone in frontline physicians and nurses with pandemic-related depression and burnout. Two weeks after the intervention, the group receiving psilocybin plus MBSR showed a significantly larger drop in depression scores (between-group difference of 4.6 points on the QIDS-SR-16). This advantage faded by six months. No serious adverse events occurred; only mild to moderate side effects were recorded. The combination also showed trends toward less burnout and demoralization and greater connectedness, but those results did not hold up after statistical correction. The small, homogeneous sample limits generalizability.
OPAL (Open@LaTrobe) (La Trobe University)
September 19, 2025
No Summary
OPAL (Open@LaTrobe) (La Trobe University)
September 19, 2025
Adding a single 25 mg dose of psilocybin to an 8-week Mindfulness-Based Stress Reduction (MBSR) program led to a significantly greater reduction in depressive symptoms among frontline physicians and nurses than MBSR alone, two weeks after the intervention ended. The between-group difference on the Quick Inventory of Depressive Symptoms was 4.6 points. This effect diminished by six months. The combination was safe, with only mild to moderate adverse events and no serious ones. Secondary measures of burnout, demoralization, and connectedness also favored the psilocybin group but did not reach statistical significance after correction. The small, homogeneous sample limits generalizability.
OPAL (Open@LaTrobe) (La Trobe University)
September 19, 2025
Adding a single 25 mg dose of psilocybin to an 8-week Mindfulness-Based Stress Reduction (MBSR) program reduced depressive symptoms more than MBSR alone in frontline physicians and nurses with pandemic-related depression and burnout. Two weeks after the intervention, the group receiving psilocybin plus MBSR showed a significantly larger drop in depression scores (between-group difference of 4.6 points on the QIDS-SR-16). This improvement was no longer significant at six months. No serious adverse events occurred, though twelve mild-to-moderate side effects were reported. The study suggests psilocybin may enhance MBSR's antidepressant effects, but larger trials are needed to confirm durability and generalizability.
OPAL (Open@LaTrobe) (La Trobe University)
July 22, 2025
A. Cioe, Patricia, S. Stang, Garrett, Azam, Danish et al.
No Summary
OPAL (Open@LaTrobe) (La Trobe University)
July 8, 2025
Psilocin, the active metabolite of psilocybin, produces psychedelic effects by activating a specific region of the brain: the medial prefrontal cortex (mPFC). In male mice, a tiny dose of psilocin injected directly into the mPFC triggered a head twitch response, a behavioral marker of psychedelic activity. Artificially activating mPFC neurons with light increased these twitches, while inhibiting them suppressed drug-induced twitches. This identifies the mPFC as a key regulator of psilocin's psychedelic effects, offering a target for developing safer therapeutic applications of psychedelics for conditions like depression.
OPAL (Open@LaTrobe) (La Trobe University)
May 7, 2025
Psilocybin use is associated with lower odds of opioid use disorder, and this association varies by race and ethnicity.
OPAL (Open@LaTrobe) (La Trobe University)
May 7, 2025
Grant Jones (338384)
Among individuals who have used psilocybin, the relationship between that use and later opioid use disorder varies by race and ethnicity. The study examines how race and ethnicity modify the association between psilocybin use and the risk of developing opioid use disorder. The findings indicate that the interaction between race/ethnicity and psilocybin use is a significant predictor of opioid use disorder, suggesting that the effects of psilocybin on opioid-related outcomes are not uniform across different racial and ethnic groups.
OPAL (Open@LaTrobe) (La Trobe University)
May 7, 2025
Race and ethnicity significantly influence whether psilocybin use is linked to lower odds of opioid use disorder (OUD). Analyzing data from over 700,000 U.S. respondents, the study found that only White and Hispanic participants showed a connection between psilocybin use and reduced OUD odds (White aOR: 0.84; Hispanic aOR: 0.68). For Black, Asian, Indigenous, and Multiracial participants, no significant association emerged. The results indicate that the potential protective effect of psilocybin against OUD is not uniform across racial and ethnic groups, highlighting the need for further research to understand these differences.
OPAL (Open@LaTrobe) (La Trobe University)
May 7, 2025
Race and ethnicity moderate the link between psilocybin use and opioid use disorder (OUD). Analyzing data from over 700,000 respondents in the National Survey on Drug Use and Health (2002–2019), the study found that only White and Hispanic participants showed a significant association between psilocybin use and lowered odds of OUD (White adjusted odds ratio: 0.84; Hispanic adjusted odds ratio: 0.68). For Black, Asian, Indigenous, and Multiracial participants, no significant association emerged. The findings suggest that the potential protective effect of psilocybin on OUD is not uniform across racial and ethnic groups.
OPAL (Open@LaTrobe) (La Trobe University)
January 1, 2013
Weissbart Hugo
No Summary